MFN.se

The transaction gives Lifecare control of established laboratory and production infrastructure at Espehaugen in Bergen, including a GMP Grade C cleanroom, together with established quality processes and personnel with relevant competence for Lifecare’s continued production development and R&D activities. Ocean TuniCell has made substantial investments in establishing and developing its production, laboratory and cleanroom infrastructure.

Under augusti 2026 har det registrerade antalet aktier respektive röster i IRLAB Therapeutics AB (”IRLAB” eller ”Bolaget”) förändrats med anledning av Bolagets nyligen genomförda företrädesemission och övertilldelningsemission av stamaktier av serie A, vilka styrelsen beslutade om den 5 maj 2026 och godkändes av den extra bolagsstämman den 5 juni 2026.

Kristiansand, 31. august 2026; Skandia Greenpower AS rapporterer et netto resultat på NOK 5,3 millioner i H1 2026 (NOK 4,2 millioner i 2025). EBITDA i H1 2026 er NOK 14,0 millioner (NOK 13,8 millioner i 2025). Selskapet har i perioden generert en fri kontantstrøm på NOK 10,9 millioner. Sterke resultater og flere milepæler i første halvår: Konsernet passerer for første gang NOK 500 millioner i omsetning i et halvår og vil sannsynligvis passerer NOK 1 milliard i omsetning i 2026.

(Verdal, August 31, 2026) Ocean GeoLoop ASAŽs (Ocean GeoLoop, OSE: OGL) subsidiary Captured AS has entered into a binding Share Purchase Agreement to sell all its shares in the subsidiary Ocean Tunicell AS to Lifecare ASA. Reference is made to the company's announcement of 19 June 2026. The company has entered into the agreement referred to in the announcement of 19 June 2026 with Lifecare ASA.

CEO comment "In the first quarter, we delivered record battery performance. The second quarter was about proving it repeats and developing our technology further. The clearest evidence is a fourfold improvement in the performance of our LiPON solid-state electrolyte, with three times improved homogeneity. Cycling also moved from bench-level glove boxes into standard test boxes, which lifts the limit on how many cells we can hold on test and how fast evidence accumulates.

Summary of the fourth quarter (April 2026 - June 2026) Net sales increased by 10,6 percent and amounted to SEK 5,658 million (5,118). Organic growth, including bolt-on acquisitions, was 6,0 percent. Operating profit (EBIT) amounted to SEK 666 million (578). Adjusted EBITA, adjusted for items affecting comparability and IFRS 16, amounted to SEK 552 million (475). Items affecting comparability amounted to SEK -15 million (-13). Profit for the period amounted to SEK 385 million (321).

During August 2026, the registered number of shares and votes in IRLAB Therapeutics AB (”IRLAB” or the "Company") has changed as a result of the Company's recently completed rights issue and overallotment issue of ordinary shares of series A, which the Board of Directors resolved on 5 May 2026 and which were approved by the Extraordinary General Meeting on 5 June 2026.

Oslo, 31 August 2026: Omda AS ("Omda" or the "Company") has mandated Pareto Securities AS and SB1 Markets AS as Joint Bookrunners to arrange a series of fixed income investor meetings commencing Tuesday, 1 September 2026. A SEK 700 million senior secured bond issue with a four-year tenor may follow, subject to market conditions.

Transactions made under Telenor ASA's share buyback program Announcement date of the share buyback program: 20 May 2026 End date of the share buyback program: 16 February 2027 Below and attached to this notice is an overview of all trades performed in the period between 24.08-28.08.26. Date Marketplace Aggregate daily volume (no.

Transaksjoner foretatt under tilbakekjøpsprogram for Telenor ASA Dato for når tilbakekjøpsprogrammet ble annonsert: 20. mai 2026 Tilbakekjøpsprogrammets varighet: 16.